Get Articles Daily from StraightStocks - Enter Email Address


  • National Debt Clock


FDA Panel Backs Glaxo’s Votrient – Analyst Blog

Source: http://www.zacks.com/stock/news/25569/FDA+Panel+Backs+Glaxo%27s+Votrient+-+Analyst+Blog
 Posted on Tuesday, October 6th, 2009 | In Investing Lessons, Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -

GlaxoSmithKline (GSK) received positive news yesterday when the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favor of the company’s experimental kidney cancer drug, Votrient (pazopanib).

Importantly, the panel voted that Votrient can benefit patients by slowing the disease, despite some risk of liver damage. We believe the company may be asked to submit data from ongoing studies to ensure that liver toxicity associated with the use of the drug does not increase over time.

Votrient is an oral vascular endothelial growth factor (VEGFr) anti-angiogenesis agent. GlaxoSmithKline is seeking FDA approval for the use of Votrient as a treatment for patients with advanced renal cell carcinoma (RCC).

Phase III data showed that the drug significantly increased progression free survival compared to placebo. Glaxo filed the candidate for FDA and E.U. approval for the treatment of RCC in December 2008 and March 2009, respectively. Glaxo is also testing Votrient in combination with Tykerb. Votrient is being designed as an alternative to Pfizer’s (PFE) Sutent and Bayer’s/Onyx’s (ONXX) Nexavar.

According to Glaxo, RCC is the most common type of kidney cancer and accounts for approximately nine out of ten cases. It is estimated that about 57,700 people will be diagnosed with kidney cancer and 13,000 people will die from the disease in the United States in 2009. In 2002, an estimated 208,000 new cases of kidney cancer were diagnosed globally.

A response from the FDA should be out later this month. While the agency is not required to follow the advice of the panel, it usually does so. We are currently modeling the product launch in 2010.
Read the full analyst report on “GSK”
Read the full analyst report on “PFE”
Read the full analyst report on “ONXX”
Zacks Investment Research

Last 5 posts by Zacks Market Commentaries
About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries

No Responses to “FDA Panel Backs Glaxo’s Votrient – Analyst Blog”

  1. FDA Panel Backs Glaxo’s Votrient – Analyst Blog | Self Directed Investor News Says:
    October 7th, 2009 at 12:59 am

    [...] Read more: FDA Panel Backs Glaxo’s Votrient – Analyst Blog [...]

Leave a Reply

Name

Email (kept private)

Website









No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.